Study of Airflow Limitation Mechanisms in Stable, Non-Smoking Asthma Patients Ages 10 to 80
Led by Gelb, Arthur F., M.D. · Updated on 2023-10-26
50
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying chronic, stable asthmatics who do not smoke, focusing on understanding what causes expiratory airflow limitation in moderate to severe persistent asthma. This research aims to identify whether the large or small airways mainly contribute to airflow problems and to explore the role of small airway obstruction and loss of lung elastic recoil. The study also evaluates how different doses of inhaled corticosteroids affect inflammation in these airways, using exhaled nitric oxide as a marker. Measurements will also be taken during naturally occurring asthma exacerbations for comparison.
Participants receive treatment with inhaled corticosteroids and long-acting beta2-agonists such as fluticasonesalmeterol or budesonideformoterol in varying doses. This is an observational study where additional treatments might include antibiotics and tapering corticosteroids. Researchers will also perform lung function studies, imaging including high-resolution CT scans, and fiberoptic bronchoscopy with optical coherence tomography to assess lung structure and function.
During the study, participants will undergo regular assessments including spirometry, measurements of exhaled nitric oxide, and lung function tests over periods ranging from 20 to 60 days and up to 5 years. Data from lung autopsies of asthmatics will be compared when available. The study monitors mechanisms of airflow limitation and presence of emphysema, aiming to better understand the disease process. Participants are observed without masking or randomization, and the total follow-up can extend from months to years.
CONDITIONS
Brief Title
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Research Team
A
Arthur F Gelb, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
ICS/LABA Combination Used in the Study
Current ICS/LABA Guideline Care
What it is
A protocol-defined ICS/LABA combination: either budesonide/formoterol or fluticasone/salmeterol, used in all enrolled asthmatic patients meeting strict eligibility criteria.
The established standard of care for persistent asthma, especially in moderate-to-severe cases, is guideline-recommended therapy with an inhaled corticosteroid plus long-acting beta agonist (ICS/LABA) combination.
Role in trial
The investigational intervention: all trial participants receive the ICS/LABA combination. There is no comparator or placebo group in the trial.
Represents best available guideline-directed therapy for persistent asthma outside of research protocols, applied in routine clinical practice.
Primary use
To study mechanisms of airflow limitation and track markers such as exhaled nitric oxide in asthmatics receiving long-term ICS/LABA therapy.
To control asthma symptoms, prevent exacerbations, and improve lung function in patients with moderate-to-severe or persistent asthma.
How it is given or performed
Delivered as inhalation therapy: budesonide/formoterol or fluticasone/salmeterol—specific dosing per protocol—twice daily for 20–60 days.
Administered via inhaler, with prescribed dosing regimens following guideline recommendations for maintenance and step-up/step-down therapy.
Evidence status
Evidence from this trial is not yet established; results have not been published in the registry.
ICS/LABA combinations are recommended by guidelines and supported by multiple studies for persistent or severe asthma, with extensive real-world and published evidence.
Important limitations
The trial is a single-group, non-randomized study without direct comparator arms, limiting interpretation of clinical effects. The observation period is relatively short for long-term asthma outcome assessment.
Although ICS/LABA is effective for many patients, some individuals continue to experience symptoms or airflow limitation despite optimal therapy. Guidelines recommend ongoing assessment and possible treatment adjustment.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 10Years - 80Years
All Genders
Eligibility Criteria
You may qualify if you...
Current non-smoking with less than 10 pack years smoking history
Stable, treated asthma
Age between 10 and 80 years
After 180 mcg albuterol by metered dose inhaler: FEV1/FVC less than 70% and FEV1 less than 80% predicted
You will not qualify if you...
Pregnancy
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 20 to 60 days
Participants receive inhaled corticosteroid and long-acting beta-agonist medications to manage asthma symptoms.
Visits as needed during treatment period
Long-term Monitoring
Duration - 1 to 5 years
Participants are observed to assess mechanisms of airflow limitation and other long-term outcomes related to asthma.
Follow-up visits may occur periodically over several years
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Similar Trials
Phase 4 Multicenter Study on Starting Airsupra in the Emergency Department to Improve Asthma Outcomes Compared to Usual Care
Study of Inflammatory Lung Diseases Including Asthma, COPD, Bronchiectasis, Cystic Fibrosis, PCD, and ILD to Understand Patient Characteristics and Improve Personalized Treatment
Phase 1 Randomized Study Comparing Pharmacokinetics of Two GSK5784283 Formulations in Healthy Adults by Injection
Evaluating Different Lung Function Tests Including Impulse Oscillometry for Diagnosing Asthma in Adults
Evaluating Two Doses of Glycopyrronium Inhaler Compared to Placebo with Budesonide and Formoterol in Children 4 to Under 12 Years with Asthma
Randomized Feasibility Study of Nocturnal CPAP Compared to Standard Care in Adults with Large Airway Collapse
Study to Assess Patient Characteristics and Outcomes in Asthma Across Different Severities in Real-World Care
A Cross-Sectional and Prospective Observational Study of Asthma Disease Burden and Control
Phase 3 Open-label Study to Assess Depemokimab as Add-on Treatment for Asthma with Type 2 Inflammation in Children Aged 6 to 11 Years
Evaluating Depemokimab as an Add-On Treatment for Adolescents and Adults with Type 2 Asthma at Risk of Exacerbations Compared to Placebo and Standard Care
Evaluating HB0056 Injection for Adults with Moderate to Severe Asthma
Randomized, Double-Blind, Placebo-Controlled Study of Safety and Effectiveness
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
In moderate-to-severe asthma patients monitoring exhaled nitric oxide during exacerbation is not a good predictor of spirometric response to oral corticosteroid.
Arthur F Gelb, Roxanna Moridzadeh, Deepak H Singh...
Unraveling the Pathophysiology of the Asthma-COPD Overlap Syndrome: Unsuspected Mild Centrilobular Emphysema Is Responsible for Loss of Lung Elastic Recoil in Never Smokers With Asthma With Persistent Expiratory Airflow Limitation.
Arthur F Gelb, Alfred Yamamoto, Eric K Verbeken...